Serine News and Research

RSS

Could environmental toxins trigger amyloid plaques in the brain? An interview with Dr Paul Alan Cox

Many Chamorro villagers on the island of Guam perished from a puzzling paralytic disease that combines aspects of ALS, Alzheimer's, and Parkinson's disease.

From Huron Digital Pathology 14 Mar 2016

Scientists discover novel drug candidate to treat breast cancer, lung cancer and melanoma

Using a new approach, scientists at The Scripps Research Institute and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.

10 Mar 2016

Food-based proteins can help address child malnutrition in developing countries

Contrary to popular belief among world relief workers, children in developing countries may not be eating enough protein, which could contribute to stunted growth, a Johns Hopkins-directed study suggests.

24 Feb 2016

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan plc today announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

30 Jan 2016

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

A new study published today in the science journal Proceedings of the Royal Society B indicates that chronic exposure to an environmental toxin may increase risk of neurodegenerative illness. Conducted by scientists at the Institute for EthnoMedicine, a non-profit medical research organization, and the University of Miami Brain Endowment Bank, the study provides a foundation for future research in Alzheimer's disease, ALS and Parkinson's disease.

25 Jan 2016

Support for enteric nervous system pathology in prodromal PD

Researchers have found positive immunostaining of α-synuclein in the enteric nervous system of patients with idiopathic rapid eye movement sleep behaviour disorder, suggesting it may have a possible role as a biomarker for prodromal Parkinson’s disease.

22 Oct 2015

Mutation that increases sphingolipid levels can lead to neurodegeneration

A mutation that increases the level of a special class of sphingolipids--molecules important to cell structure and signaling--can lead to neurodegeneration due to problems with neuronal membranes, reports a research team led by Jackson Laboratory Research Scientist Lihong Zhao, Ph.D. and Professor Patsy Nishina, Ph.D.

7 Oct 2015

New study finds link between maternal protein deficiency during pregnancy and metabolic diseases in offspring

A new study has uncovered the genetic processes that link insufficient protein consumption during pregnancy with the development of muscle problems in mothers and their male offspring.

19 Sep 2015

Scientists identify new drug target to treat heart arrhythmias

Scientists at The Ohio State University Davis Heart and Lung Research Institute have identified a new target they hope will help make the next drug discovery for patients suffering from heart arrhythmias happen sooner.

9 Sep 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

Omeros' OMS721 granted FDA Fast Track designation for treatment of atypical hemolytic uremic syndrome

Omeros Corporation today announced that the U.S. Food and Drug Administration granted Fast Track designation to OMS721 for the treatment of patients with atypical hemolytic uremic syndrome (aHUS). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

23 Jul 2015

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).

22 Jul 2015

Abide Therapeutics begins Phase 1a study of ABX-1431 investigational endocannabinoid system modulator

Abide Therapeutics, a developer of innovative pharmaceuticals, announced today initiation of enrollment and dosing of the first subject in a Phase 1a clinical study of ABX-1431, a first-in-class, investigational endocannabinoid system modulator.

7 Jul 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Combination of Mekinist and Tafinlar drugs improves outcome in patients with metastatic melanoma

Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar monotherapy alone.

1 Jun 2015

Scientists uncover role of HTRA3 protease in Cockayne syndrome

Scientists from the Institut Pasteur and CNRS, in collaboration with scientists from the Institut Gustave Roussy and CEA, have succeeded in restoring normal activity in cells isolated from patients with the premature aging disease Cockayne syndrome. They have uncovered the role played in these cells by an enzyme, the HTRA3 protease.

22 May 2015

Alnylam files clinical trial application for alpha-1 liver disease, presents data at DDW

Alnylam Pharmaceuticals, Inc. has announced that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease).

19 May 2015

Biologists discover vulnerability of brain cancer cells

Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.

9 Apr 2015

New treatment could halt growth of tumours in prostate cancer patients

Scientists believe a new treatment, shown to be effective in mice, could halt the growth of tumours in patients with prostate cancer.

11 Nov 2014